$LQDA

Schundler Russell sold $1.1M of LQDA

Schundler Russell (General Counsel) sold 14,738 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $1.05M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schundler Russell
Published Jul 15, 2026, 12:04 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to change the fundamental outlook.

03

What to watch

The article does not disclose whether additional insiders sold, whether there were concurrent buybacks, or any new company-specific catalysts; those would matter more for price.

Relevance 5/10Novelty 4/10Timing: Filed 2026-07-14 after trades on 2026-07-13

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by its General Counsel.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia Corp Form 4 shows General Counsel Schundler Russell sold 14,738 shares in open-market trades totaling about $1.05M under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief unless accompanied by other new fundamentals.

Evidence & confidence

The filing is a primary-source Form 4 transaction with explicit 10b5-1 pre-arrangement, and the article provides no new operational, financial, or regulatory developments.

Market effects

No clear sector read-through from a single officer sale disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales under a 10b5-1 plan can be purely mechanical for liquidity or tax planning, so the signal may be overstated.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure.

  • Schundler Russell

    General Counsel who sold 14,738 shares in two trades.

  • 10b5-1 plan

    Pre-arranged plan cited as Yes, suggesting scheduled/structured selling.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient